GlobeNewswire Inc.··NaRezolute Gears Up for Major Conference Season with Phase 3 Hyperinsulinism Data
$RZLT to present Phase 3 sunRIZE trial results at major investor conferences May-June 2026, showcasing glycemic control improvements in rare pediatric disease.
RZLTPhase 3 clinical trialinvestor conference